Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2017
Jun. 30, 2016
Current assets:    
Cash $ 12,422 $ 23,014
Accounts receivable - trade 128 484
Accounts receivable - unbilled 0 122
Work in process 60 22
Prepaid expenses and other current assets 374 264
Total current assets 12,984 23,906
Fixed assets, net of accumulated depreciation 25,794 25,574
Intangible assets, net of accumulated amortization 1,895 2,092
Security deposit 25 28
Total Assets 40,698 51,600
Current liabilities:    
Accounts payable (related party of $199 and $200 as of March 31, 2017 and June 30, 2016, respectively) 1,391 1,177
Accrued expenses (related party of $784 and $623 as of March 31, 2017 and June 30, 2016, respectively) 957 920
Capital lease obligation - current portion 180 170
Deferred revenue 93 24
Total Current Liabilities 2,621 2,291
Capital lease obligation - net of current portion 25,129 25,265
Total Liabilities 27,750 27,556
Commitments and Contingencies
iBio, Inc. Stockholders’ Equity:    
Preferred stock - $0.001 value; 1,000,000 shares authorized; 1 and 0 shares issued and outstanding as of March 31, 2017 and June 30, 2016, respectively 0 0
Common stock - $0.001 par value; 175,000,000 shares authorized; 89,118,510 and 89,109,410 shares issued and outstanding as of March 31, 2017 and June 30, 2016, respectively 89 89
Additional paid-in capital 80,680 67,468
Accumulated other comprehensive loss (29) (29)
Accumulated deficit (67,794) (57,591)
Total iBio, Inc. Stockholders’ Equity 12,946 9,937
Noncontrolling interest 2 14,107
Total Equity 12,948 24,044
Total Liabilities and Equity $ 40,698 $ 51,600